Harvard Health Columns

Despite Benefit, Drug Prices Still High For Seniors

The new drug-benefit program for Medicare beneficiaries may not substantially reduce the actual cost of drugs for many seniors and others with Medicare insurance. The new regulations that took effect earlier this year were supposed to lower prescription-drug costs by offering discounts on brand-name drugs of 10 percent to 25 percent. However, the average price of the most popular drugs is rising much faster than the current rate of inflation (as measured by…

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In